HCPCS Level II code P3000 represents a screening Papanicolaou (Pap) smear of the cervix or vagina, up to three smears, performed by a technician under physician supervision. This code captures the specimen collection component of cervical/vaginal cytology screening, a routine preventive service that contributes to early detection of precancerous lesions and cervical cancer. Nationally, clear coding supports accurate quality measurement and appropriate claims processing for commonly delivered preventive women's health services.

Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare and Medicare. Readers will find concise benchmarks and contextual information on where this service is typically delivered, common clinical indications, and how the code aligns with service lines. The publication covers reimbursement context, billing practice considerations, and potential policy updates affecting screening services, presented for a national audience.

This summary is intended to orient clinicians, billing staff, and policy analysts to the clinical meaning and administrative use of P3000, and to identify areas where payers' coverage and claims handling practices can affect access and reporting for cervical and vaginal cytology screening.